Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Aurinia Pharmaceuticals has undergone a major management overhaul, with fund manager and activist investor Kevin Tang appointed as the CEO. AUPH's COO and CFO have also been replaced. Lupkynis's net product sales reached $271.3M in 2025, up 25.5% YoY, with 2026 guidance for $305M–$315M, possibly conservative given the company's previous beat of initial 2025 guidance. Aritinercept will be evaluated in two autoimmune diseases, with one clinical study already underway and another set to commence in H1 2026, although the exact indications have not been disclosed.

Aurinia Pharmaceuticals announced a complete overhaul of its C-suite on Monday, sparking both the biotech stock and hopes of an acquisition.

CAYMAN ISLANDS--(BUSINESS WIRE)--MKT Capital Ltd. (together with its affiliates, “MKT Capital” or “we”), a significant long-term shareholder of Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (“Aurinia” or the “Company”), today issued the following statement in response to the Company's announcement that Kevin Tang has been appointed Chief Executive Officer, effective immediately. Antoine Khalife, Founder of MKT Capital, stated: “Today marks a watershed moment for Aurinia shareholders. Since 2019,.

The company said Kevin Tang, Aurinia's chair of the board, will succeed Peter Greenleaf as CEO, while Greenleaf will remain on as a consultant to support the transition.

ROCKVILLE, Maryland & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Announces Management Transition.

Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) shares are trading lower Thursday afternoon after the lupus-focused drugmaker posted fourth quarter earnings and raised expectations for continued growth in 2026.

Aurinia Pharmaceuticals Inc. (AUPH) Q4 2025 Earnings Call Transcript